Synthesis, In-silico and In-vitro analysis of hydrazones as potential antituberculosis agents.

Clicks: 278
ID: 104541
2020
Tuberculosis (TB) is remaining a major cause of mortality and illness as reported by W.H.O in 2019. The WHO report also mentioned the fact that about 10.0 million people fell ill with tuberculosis in the year 2018. Hydrazide-hydrazones having azomethine group (-NH-N=CH-) connected with carbonyl group is reported for the number of bioactivities like anti-inflammatory, anticonvulsant, anticancer, antiviral and antiprotozoal.The objective of our current study is to design and synthesis of more potent Hydrazide-hydrazones containing anti-Tubercular agents.In the current study, we have synthesized 10 hydrazones (3a-3j) by stirring corresponding benzohydrazides (2) with substituted aldehydes (1a-j) in ethanol as a solvent and acetic acid as a catalyst at room temperature. All synthesized compounds were characterized by various spectroscopic techniques including Elemental analysis, UV, Fluorescence, FT-IR and 1H-NMR. Compounds (3a-3j) were tested for in-vitro anti-TB activity using Microplate Alamar Blue assay (MABA).All our synthesized compounds (3a-3j) were found to be potent against Mycobacteria tuberculosis (H37RV strain) with MIC (minimum inhibitory concentrations) values of 3.125-50 µg/mL. Synthesized compounds were also tested for in-silico analysis using diffent softwares for their Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) analysis.Our current study will definitely help the medicinal chemists for better designing of newer potent anti-Tubercular agents.
Reference Key
thorat2020synthesiscurrent Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Thorat, Bapu R;Mali, Suraj;Rani, Deepa;Yamgar, Ramesh;
Journal current computer-aided drug design
Year 2020
DOI 10.2174/1573409916666200302120942
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.